Belite Bio (ADR) (BLTE)
Develops oral investigational therapies for retinal and metabolic diseases.
$163.00
Pre-market+1.55 (+0.96%)
At close$161.45(+3.03%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions75 holders · as of Mar 31, 2026 | 22.74% | 9.12M ADS | |
| Insiders5 holders · as of Aug 14, 2026 | 1.83% | 735.2K ADS | |
| Strategic holders1 holder · as of Jan 21, 2025 | 42.65% | 17.10M ADS | |
| Otherremainder | 32.78% | 13.14M ADS |
40.09M ADS as of Aug 22, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Institutions13F, as of Mar 31, 2026
75 holders · 9.12M shares · 28 new positions · 54 increased · 15 reduced · 22 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Darwin Global Management, Ltd. | 3.06M | 7.63% | +29.7K | May 15, 2026 |
| Paradigm Biocapital Advisors LP | 1.11M | 2.78% | +1.11Mnew | May 15, 2026 |
| UBS Group AG | 768.4K | 1.92% | +639.6K | May 5, 2026 |
| RTW Investments, LP | 715.3K | 1.78% | 0 | May 15, 2026 |
| Millennium Management LLC | 570.1K | 1.42% | +11.2K | May 15, 2026 |
| Holocene Advisors, LP | 494.5K | 1.23% | +410.4K | May 15, 2026 |
| Eventide Asset Management, LLC | 357.7K | 0.89% | −25.4K | May 15, 2026 |
| Deerfield Management Company, L.P. (Series C) | 304.0K | 0.76% | +70.2K | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Lin Bioscience International Ltd. | 53.70% | 17.10M | 13G | Jan 21, 2025 ↗ |
| Darwin Global Management, Ltd. | 8.10% | 3.03M | 13G | Feb 17, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 12, 2026 | Yu-Hsin Lindirector, officer: Chief Executive Officer | Sale · 2 lots | 365 | $180.35 | 170,569 |
| Aug 12, 2026 | Hao-Yuan Chuangdirector, officer: Chief Financial Officer | Sale · 2 lots | 367 | $180.35 | 93,433 |
| Jun 18, 2026 | Hendrik Peter Schollofficer: Chief Medical Officer | Sale · 5 lots | 10,000 | $145.24 | 15,000 |
| Jun 16, 2026 | Hendrik Peter Schollofficer: Chief Medical Officer | Sale · 8 lots | 10,000 | $140.57 | 25,000 |
| May 7, 2026 | Nathan L. Mataofficer: Chief Scientific Officer | Sale · 4 lots | 666 | $153.21 | 0 |
| May 6, 2026 | Nathan L. Mataofficer: Chief Scientific Officer | Sale · 6 lots | 1,000 | $153.84 | 666 |
| May 5, 2026 | Nathan L. Mataofficer: Chief Scientific Officer | Sale · 6 lots | 1,000 | $155.50 | 1,666 |
| May 4, 2026 | Nathan L. Mataofficer: Chief Scientific Officer | Sale · 5 lots | 1,000 | $155.64 | 2,666 |
| May 1, 2026 | Nathan L. Mataofficer: Chief Scientific Officer | Sale · 8 lots | 1,000 | $155.78 | 3,666 |
| Apr 30, 2026 | Nathan L. Mataofficer: Chief Scientific Officer | Sale · 4 lots | 1,000 | $156.97 | 4,666 |
CongressHouse and Senate disclosures
Not reported.